Recent studies have highlighted that SGLT2 inhibitors, including canagliflozin and Dapagliflozin, can inhibit cancer and colorectal cell growth through inhibition of SGLT2-mediated glucose uptake (Dutka et al., 2022). The gene discussed is SLC5A2; the disease is cancer.